Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 304 participants.
Also called NCT06723717
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 304 participants
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Registry
-
NCT06723717
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT06723717. Randomized; single masking; primary purpose prevention. Start 2025-09-26 (actual); primary completion 2028-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
- Acronym
- RESET
- Condition
- Ruptured Aneurysm of Intracranial Artery
- Condition
- SAH (Subarachnoid Hemorrhage)
- Condition
- Delayed Cerebral Ischemia
- Intervention (Drug)
- Daily infusion of dornase alfa
- Lead sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Record details
- Record id
cardio:ct-nct06723717- Content hash
923001255526b7e57d30e326eb97f22f080be315fa93b2ab6870fce425f5fcca